News | Hypertension | March 23, 2022

FDA Recalls Quinapril Hydrochloride and Hydrochlorothiazide Tablets by Pfizer

The tablets are being recalled due to N-NitrosoQuinapril content

MedWatch, The FDA Safety Information and Adverse Event Reporting Program, announced today that Pfizer is recalling Accuretic (quinapril hydrochloride/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril HCL and hydrochlorothiazide and quinapril HCl/hydrochlorothiazide) due to the presence of a nitrosamine, N-nitroso-quinapril, above the Acceptable Daily Intake level.

March 23, 2022 — MedWatch, The FDA Safety Information and Adverse Event Reporting Program, announced today that Pfizer is recalling Accuretic (quinapril hydrochloride/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril HCL and hydrochlorothiazide and quinapril HCl/hydrochlorothiazide) due to the presence of a nitrosamine, N-nitroso-quinapril, above the Acceptable Daily Intake level. Pfizer will recall six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.

Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. Everyone is exposed to some level of nitrosamines. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time.

The products being recalled are indicated for the treatment of hypertension. To date, Pfizer is not aware of reports of adverse events that have been assessed to be related to this recall.

Patients who are taking this product should consult with their healthcare provider or pharmacy to determine if they have the affected product. Patients with the affected product should contact the company. Patients currently taking the products should consult with their doctor about alternative treatment options. Healthcare Professionals with questions regarding this recall can contact the company.

Health professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report online.
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on form, or submit by fax to 1-800-FDA-0178.

The full expanded list of recalled batches can be found here.

For more information: www.fda.gov

 


Related Content

News | Hypertension

September 26, 2022 — ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the ...

Home September 26, 2022
Home
News | Hypertension

September 20, 2022 — Orchestra BioMed, Inc., a biomedical innovation company accelerating high-impact technologies to ...

Home September 20, 2022
Home
News | Hypertension

September 12, 2022 — Researchers at the National Institutes of Health have found that a novel blood test can be used to ...

Home September 12, 2022
Home
News | Hypertension

August 8, 2022 — Cardiovascular diseases remain a leading cause of death around the world. A primary contributor to ...

Home August 08, 2022
Home
News | Hypertension

July 29, 2022 — ReCor Medical, Inc. and Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings Co ...

Home July 29, 2022
Home
News | Hypertension

April 7, 2022 – Among patients undergoing non-cardiac surgery who were also on blood pressure medications, a ...

Home April 07, 2022
Home
News | Hypertension
February 25, 2022 – University of Alabama at Birmingham researchers are calling for a wider study of racial differences ...
Home February 25, 2022
Home
News | Hypertension

November 18, 2021 — Village doctors who were community health workers in rural China were trained and successfully ...

Home November 18, 2021
Home
News | Hypertension

November 12, 2021 — Orchestra BioMed Inc. announced multiple presentations of long-term clinical results and ISH ...

Home November 12, 2021
Home
News | Hypertension

November 9, 2021 — Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound ...

Home November 09, 2021
Home
Subscribe Now